Oral Anti Diabetes Drugs Market - 2024-2031
Oral Anti Diabetes Drugs Market reached USD 80.8 billion in 2031 and, growing with a CAGR of 8.00% during the forecast period 2031-2035.
The Oral Anti Diabetes Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Oral Anti Diabetes Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Class
Both primary and secondary data sources have been used in the global Oral Anti Diabetes Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Oral Anti Diabetes Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Oral Anti Diabetes Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Class
- Biguanides*
- Metformin
- Alpha-glucosidase inhibitors
- Dopamine -D2 Receptor Agonist
- Bromocriptin (Cycloset)
- Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Farxiga/Forxiga (Dapagliflozin)
- Suglat (Ipragliflozin)
- Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
- Januvia (Sitagliptin)
- Onglyza (Saxagliptin)
- Tradjenta (Linagliptin)
- Vipidia/Nesina (Alogliptin)
- Galvus (Vildagliptin)
- Sulfonylureas
- Meglitinides
- Liquid*
- Capsule
- Tablet
- Hospital Pharmacies*
- Retail Pharmacies
- Online Pharmacies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Oral Anti Diabetes Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Class
3.2. Snippet by Dosage Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of diabetes
4.1.2. Restraints
4.1.2.1. Side effects associated with diabetic drugs
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. ARTIFICIAL INTELLIGENCE ANALYSIS
9. BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Biguanides*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.2.1. Metformin
9.3. Alpha-glucosidase inhibitors
9.4. Dopamine -D2 Receptor Agonist
9.4.1. Bromocriptin (Cycloset)
9.5. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
9.5.1. Invokana (Canagliflozin)
9.5.2. Jardiance (Empagliflozin)
9.5.3. Farxiga/Forxiga (Dapagliflozin)
9.5.4. Suglat (Ipragliflozin)
9.6. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
9.6.1. Januvia (Sitagliptin)
9.6.2. Onglyza (Saxagliptin)
9.6.3. Tradjenta (Linagliptin)
9.6.4. Vipidia/Nesina (Alogliptin)
9.6.5. Galvus (Vildagliptin)
9.7. Sulfonylureas
9.8. Meglitinides
10. BY DOSAGE TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
10.1.2. Market Attractiveness Index, By Dosage Type
10.2. Liquid*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Capsule
10.4. Tablet
11. BY DISTRIBUTION CHANNEL
11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2. Market Attractiveness Index, By Distribution Channel
11.3. Hospital Pharmacies*
11.3.1. Introduction
11.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.4. Retail Pharmacies
11.5. Online Pharmacies
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. COMPANY PROFILES
14.1. Glenmark Pharma*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Abbott
14.3. Biocon
14.4. Sanofi
14.5. Sunpharma
14.6. Novartis
14.7. Novo Nordisk
14.8. Merck
14.9. GlaxoSmithKline
14.10. Bristol-Myers Squibb (*LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Class
3.2. Snippet by Dosage Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of diabetes
4.1.2. Restraints
4.1.2.1. Side effects associated with diabetic drugs
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. ARTIFICIAL INTELLIGENCE ANALYSIS
9. BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Biguanides*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.2.1. Metformin
9.3. Alpha-glucosidase inhibitors
9.4. Dopamine -D2 Receptor Agonist
9.4.1. Bromocriptin (Cycloset)
9.5. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
9.5.1. Invokana (Canagliflozin)
9.5.2. Jardiance (Empagliflozin)
9.5.3. Farxiga/Forxiga (Dapagliflozin)
9.5.4. Suglat (Ipragliflozin)
9.6. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
9.6.1. Januvia (Sitagliptin)
9.6.2. Onglyza (Saxagliptin)
9.6.3. Tradjenta (Linagliptin)
9.6.4. Vipidia/Nesina (Alogliptin)
9.6.5. Galvus (Vildagliptin)
9.7. Sulfonylureas
9.8. Meglitinides
10. BY DOSAGE TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
10.1.2. Market Attractiveness Index, By Dosage Type
10.2. Liquid*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Capsule
10.4. Tablet
11. BY DISTRIBUTION CHANNEL
11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2. Market Attractiveness Index, By Distribution Channel
11.3. Hospital Pharmacies*
11.3.1. Introduction
11.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.4. Retail Pharmacies
11.5. Online Pharmacies
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. COMPANY PROFILES
14.1. Glenmark Pharma*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Abbott
14.3. Biocon
14.4. Sanofi
14.5. Sunpharma
14.6. Novartis
14.7. Novo Nordisk
14.8. Merck
14.9. GlaxoSmithKline
14.10. Bristol-Myers Squibb (*LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
